⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease. We randomly assigned 5518 patients with type 2 diabetes who were being treated with open-label simvastatin to receive either masked fenofibrate or placebo.
Coeff. authors = avg(0.65, 1.00) = 0.83
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.83, 0.95) = 0.83← lowest dominates
Final coefficient : 0.83
Final score = 47.3/52.8 × 0.83 × 100 = 75/100
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV — 2019 · The New England journal of medicine
Contrasted resultsCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL — 2018 · The New England journal of medicine
Contrasted resultsEzetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP — 2015 · The New England journal of medicine
Contrasted resultsIntensive lipid lowering with atorvastatin in patients with stable coronary disease
LaRosa JC — 2005 · The New England Journal of Medicine
Contrasted resultsEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B — 2015 · New England Journal of Medicine